$49.27
2.62% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US30063P1057
Symbol
EXAS

Exact Sciences Corporation Stock price

$49.27
+2.44 5.21% 1M
+1.72 3.62% 6M
-6.92 12.32% YTD
-10.74 17.90% 1Y
+13.18 36.52% 3Y
-27.13 35.51% 5Y
+28.37 135.74% 10Y
+46.82 1,911.02% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
+1.26 2.62%
ISIN
US30063P1057
Symbol
EXAS
Industry

Key metrics

Basic
Market capitalization
$9.3b
Enterprise Value
$10.8b
Net debt
$1.5b
Cash
$858.4m
Shares outstanding
189.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.2 | 2.9
EV/Sales
3.7 | 3.4
EV/FCF
86.7
P/B
3.8
Financial Health
Equity Ratio
40.5%
Return on Equity
-42.8%
ROCE
-2.9%
ROIC
-3.1%
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$2.9b | $3.2b
EBITDA
$66.5m | $446.2m
EBIT
$-150.8m | $-107.2m
Net Income
$-1.0b | $-113.0m
Free Cash Flow
$124.6m
Growth (TTM | estimate)
Revenue
12.6% | 16.5%
EBITDA
175.1% | 365.4%
EBIT
16.9% | 40.2%
Net Income
-474.4% | 89.0%
Free Cash Flow
907.7%
Margin (TTM | estimate)
Gross
68.2%
EBITDA
2.3% | 13.9%
EBIT
-5.1%
Net
-34.2% | -3.5%
Free Cash Flow
4.2%
More
EPS
$-5.3
FCF per Share
$0.7
Short interest
5.7%
Employees
7k
Rev per Employee
$400.0k
Show more

Is Exact Sciences Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Exact Sciences Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Exact Sciences Corporation forecast:

27x Buy
84%
5x Hold
16%

Analyst Opinions

32 Analysts have issued a Exact Sciences Corporation forecast:

Buy
84%
Hold
16%

Financial data from Exact Sciences Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,940 2,940
13% 13%
100%
- Direct Costs 935 935
34% 34%
32%
2,005 2,005
5% 5%
68%
- Selling and Administrative Expenses 1,723 1,723
6% 6%
59%
- Research and Development Expense 414 414
10% 10%
14%
66 66
175% 175%
2%
- Depreciation and Amortization 217 217
134% 134%
7%
EBIT (Operating Income) EBIT -151 -151
17% 17%
-5%
Net Profit -1,005 -1,005
474% 474%
-34%

In millions USD.

Don't miss a Thing! We will send you all news about Exact Sciences Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exact Sciences Corporation Stock News

Neutral
Seeking Alpha
about 11 hours ago
Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good afternoon.
Neutral
Business Wire
13 days ago
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that Exact Sciences has withdrawn its motion for a preliminary injunction regarding the '781 patent and the ‘746 patent.
Neutral
Business Wire
16 days ago
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. Wells Fargo Healthcare Conference, Boston Fireside chat on Wednesday, September 3, 2025 at 1:30 p.m. ET Baird Global Healthcare Conf...
More Exact Sciences Corporation News

Company Profile

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Head office United States
CEO Kevin Conroy
Employees 6,950
Founded 1995
Website www.exactsciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today